0000896264-26-000014
SEC filingUSANA Health Sciences, Inc. announced Q4 and FY 2025 financial results with net sales of $226.2 million and $925.3 million, respectively, alongside a Q4 GAAP net loss of $1.8 million due to $7.0 million impairment and $6.5 million cost realignment charges, and provided FY 2026 guidance for net sales of $925 million to $1.0 billion. The filing incorporates Exhibits 99.1 and 99.2 detailing results and outlook.